Verge Genomics and Ferrer to co-develop ALS drug candidate VRG50635
According to the terms of the agreement, Ferrer will gain the exclusive rights to co-develop and market VRG50635…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
26 Mar 24
According to the terms of the agreement, Ferrer will gain the exclusive rights to co-develop and market VRG50635…
26 Mar 24
AUD 17 Million Grant over 5 Years Will Fund Next-Generation TB Cures
26 Mar 24
Hub will focus on supporting global use of new treatments that effectively treated drug-resistant TB in 98% of…
25 Mar 24
The FDA approval of Opsynvi, a combination of two proven treatments with established efficacy and safety profiles into…
25 Mar 24
The approval was based on the findings from the confirmatory Phase 3 MIRASOL trial in which Elahere treatment…
25 Mar 24
The analyses revealed that Rexulti was linked to reductions in both overall neuropsychiatric symptoms and agitation symptoms when…
25 Mar 24
The label expansions are for the prevention of heart attacks and cardiovascular procedures in primary as well as…
22 Mar 24
The FDA approval is supported by the results from EPIDYS, a randomized, double-blind, placebo-controlled 18-month Phase 3 clinical…
22 Mar 24
The positive CHMP opinion is based on results from the ONWARDS phase 3a clinical trial programme
21 Mar 24
The deal is anticipated to boost Lonza's large-scale biologics manufacturing capacity and will also help the firm cope…